TY  - JOUR
A1  - Bolm, Louisa
A1  - Zemskov, Sergii
A1  - Zeller, Maria
A1  - Baba, Taisuke
A1  - Roldan, Jorge
A1  - Harrison, Jon M.
A1  - Petruch, Natalie
A1  - Sato, Hiroki
A1  - Petrova, Ekaterina
A1  - Lapshyn, Hryhoriy
A1  - Braun, Ruediger
A1  - Honselmann, Kim C.
A1  - Hummel, Richard
A1  - Dronov, Oleksii
A1  - Kirichenko, Alexander V.
A1  - Klinkhammer-Schalke, Monika
A1  - Kleihues-van Tol, Kees
A1  - Zeissig, Sylke R.
A1  - Rades, Dirk
A1  - Keck, Tobias
A1  - Fernandez-del Castillo, Carlos
A1  - Wellner, Ulrich F.
A1  - Wegner, Rodney E.
T1  - Concepts and outcomes of perioperative therapy in stage IA-III pancreatic cancer — a cross-validation of the National Cancer Database (NCDB) and the German Cancer Registry Group of the Society of German Tumor Centers (GCRG/ADT)
JF  - Cancers
N2  - (1) Background: The aim of this study is to assess perioperative therapy in stage IA-III pancreatic cancer cross-validating the German Cancer Registry Group of the Society of German Tumor Centers — Network for Care, Quality, and Research in Oncology, Berlin (GCRG/ADT) and the National Cancer Database (NCDB). (2) Methods: Patients with clinical stage IA-III PDAC undergoing surgery alone (OP), neoadjuvant therapy (TX) + surgery (neo + OP), surgery+adjuvantTX (OP + adj) and neoadjuvantTX + surgery + adjuvantTX (neo + OP + adj) were identified. Baseline characteristics, histopathological parameters, and overall survival (OS) were evaluated. (3) Results: 1392 patients from the GCRG/ADT and 29,081 patients from the NCDB were included. Patient selection and strategies of perioperative therapy remained consistent across the registries for stage IA-III pancreatic cancer. Combined neo + OP + adj was associated with prolonged OS as compared to neo + OP alone (17.8 m vs. 21.3 m, p = 0.012) across all stages in the GCRG/ADT registry. Similarly, OS with neo + OP + adj was improved as compared to neo + OP in the NCDB registry (26.4 m vs. 35.4 m, p < 0.001). (4) Conclusion: The cross-validation study demonstrated similar concepts and patient selection criteria of perioperative therapy across clinical stages of PDAC. Neoadjuvant therapy combined with adjuvant therapy is associated with improved overall survival as compared to either therapy alone.
KW  - pancreatic cancer
KW  - perioperative therapy
KW  - neoadjuvant therapy
KW  - pancreatic surgery
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-262174
SN  - 2072-6694
VL  - 14
IS  - 4
ER  - 
TY  - JOUR
A1  - Kist, Markus
A1  - Thomaschewski, Michael
A1  - Keck, Yannick
A1  - Abdalla, Thaer S. A.
A1  - Zeissig, Sylke Ruth
A1  - Kleihues-van Tol, Kees
A1  - Wellner, Ulrich Friedrich
A1  - Keck, Tobias
A1  - Hoeppner, Jens
A1  - Hummel, Richard
T1  - Specifics of young gastric cancer patients: a population-based analysis of 46,110 patients with gastric cancer from the German Clinical Cancer Registry Group
JF  - Cancers
N2  - Introduction: 2–8% of all gastric cancer occurs at a younger age, also known as early-onset gastric cancer (EOGC). The aim of the present work was to use clinical registry data to classify and characterize the young cohort of patients with gastric cancer more precisely. Methods: German Cancer Registry Group of the Society of German Tumor Centers—Network for Care, Quality and Research in Oncology (ADT)was queried for patients with gastric cancer from 2000–2016. An approach that stratified relative distributions of histological subtypes of gastric adenocarcinoma according to age percentiles was used to define and characterize EOGC. Demographics, tumor characteristics, treatment and survival were analyzed. Results: A total of 46,110 patients were included. Comparison of different groups of age with incidences of histological subtypes showed that incidence of signet ring cell carcinoma (SRCC) increased with decreasing age and exceeded pooled incidences of diffuse and intestinal type tumors in the youngest 20% of patients. We selected this group with median age of 53 as EOGC. The proportion of female patients was lower in EOGC than that of elderly patients (43% versus 45%; p < 0.001). EOGC presented more advanced and undifferentiated tumors with G3/4 stages in 77% versus 62%, T3/4 stages in 51% versus 48%, nodal positive tumors in 57% versus 53% and metastasis in 35% versus 30% (p < 0.001) and received less curative treatment (42% versus 52%; p < 0.001). Survival of EOGC was significantly better (five-years survival: 44% versus 31% (p < 0.0001), with age as independent predictor of better survival (HR 0.61; p < 0.0001). Conclusion: With this population-based registry study we were able to objectively define a cohort of patients referred to as EOGC. Despite more aggressive/advanced tumors and less curative treatment, survival was significantly better compared to elderly patients, and age was identified as an independent predictor for better survival.
KW  - gastric cancer in young patients
KW  - german clinical cancer registry group
KW  - early-onset gastric cancer patients
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-297473
SN  - 2072-6694
VL  - 14
IS  - 23
ER  -